Mumbai | 07-Oct-2025, 09:55 IST — Filed on 07-Oct-2025 via NSE Circular
Shilpa Medicare Ltd has announced that its bonus shares have been admitted to dealings on the National Stock Exchange (NSE) effective Tuesday, October 7, 2025.
Corporate Action Completion
The NSE circular confirms that the new bonus shares are listed under the symbol SHILPAMED, with ISIN INE790G01031. The record date for the entitlement was October 3, 2025, while the deemed allotment date was October 6, 2025.
Post-bonus, the company’s paid-up equity share capital now stands at 9,77,90,908 shares, covering distinctive numbers from 97,790,909 to 1,95,581,816. This move marks the completion of the corporate action cycle, resetting the company’s free-float and market capitalization math from today’s trading session.
Why It Matters
- Adjusted Pricing: Bonus shares effectively reduce the quoted market price per share while maintaining shareholder wealth, improving liquidity.
- Broader Base: An expanded equity base enhances retail participation and often helps in price discovery.
- F&O Impact: With the corporate action complete, derivative contracts on the stock may undergo revision subject to exchange circulars later this quarter.
What to Watch
- Opening prints vs pre-bonus adjusted price: The first hour of trade will indicate how smoothly the adjusted price is absorbed by the market.
- Delivery percentages: Tracking delivery ratios in the first three sessions will provide insight into whether long-term holders are absorbing supply.
- F&O Eligibility Updates: Any follow-up circulars from NSE on revised lot size or eligibility for F&O inclusion.
Company Profile: Shilpa Medicare Ltd
- Sector: Mid-cap pharmaceutical company, focused on oncology APIs and formulations.
- Headquarters: Raichur, Karnataka.
- Core Business: Manufacturing and R&D in oncology and specialty pharmaceuticals.
- Promoters: Family-led management with long-standing expertise in pharma exports.
- FY25 Financials: Revenue ~₹1,530 crore; Net Profit ~₹125 crore.
Recent Performance
- FY23: Revenue ₹1,420 Cr | Net Profit ₹105 Cr
- FY24: Revenue ₹1,475 Cr | Net Profit ₹115 Cr
- FY25: Revenue ₹1,530 Cr | Net Profit ₹125 Cr
Steady growth has been aided by expansion in oncology formulations and new market approvals.
Outlook
Market watchers note that bonus share listings typically generate short-term liquidity-driven activity. For Shilpa Medicare, the reset in share price levels could improve retail visibility. Investors will closely track whether the company leverages this corporate action to expand its base of shareholders and enhance trading volumes in the run-up to Q2 results.
